31 patents
Page 2 of 2
Utility
Recombinant Nucleic Acids Encoding Cosmetic Protein(s) for Aesthetic Applications
18 Feb 21
The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding one or more cosmetic proteins (e.g., one or more human collagen proteins); viruses comprising the recombinant nucleic acids; compositions (e.g., cosmetic formulations) comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.
Suma KRISHNAN, Trevor Parry, Pooja Agarwal
Filed: 29 Jun 20
Utility
Compositions and methods for delivering CFTR polypeptides
9 Nov 20
The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide (e.g., a human CFTR polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of a chronic lung disease, such as cystic fibrosis); and articles of manufacture or kits thereof.
Trevor Parry, Suma Krishnan, Pooja Agarwal
Filed: 6 Feb 20
Utility
Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
28 Sep 20
The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding one or more cosmetic proteins (e.g., one or more human collagen proteins); viruses comprising the recombinant nucleic acids; compositions (e.g., cosmetic formulations) comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.
Suma Krishnan, Trevor Parry, Pooja Agarwal
Filed: 25 Apr 19
Utility
Compositions and Methods for Delivering CFTR Polypeptides
12 Aug 20
The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide (e.g., a human CFTR polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of a chronic lung disease, such as cystic fibrosis); and articles of manufacture or kits thereof.
TREVOR PARRY, SUMA KRISHNAN, KRISH KRISHNAN, POOJA AGARWAL
Filed: 6 Feb 20
Utility
Compositions and Methods for the Treatment of Autosomal Recessive Congenital Ichthyosis
24 Jun 20
The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a transglutaminase (TGM) polypeptide (e.g., a Transglutaminase-1 (TGM1) polypeptide); viruses comprising the recombinant nucleic acids; compositions comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.
Suma KRISHNAN, Pooja AGARWAL, John C. FREEDMAN, Mark E. O'MALLEY, Lauren K. REGULA
Filed: 2 Jan 20
Utility
Compositions and Methods for the Treatment of Wounds, Disorders, and Diseases of the Skin
1 Apr 20
The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject.
Suma KRISHNAN, Pooja AGARWAL
Filed: 9 Oct 19
Utility
Compositions and Methods for the Treatment of Netherton Syndrome
25 Mar 20
The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a Serine Protease Inhibitor Kazal-type (SPINK) polypeptide (e.g., a SPINK5 polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of Netherton Syndrome); and articles of manufacture or kits thereof.
Pooja AGARWAL, Suma KRISHNAN, John C. FREEDMAN
Filed: 23 Sep 19
Utility
Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
6 Jan 20
The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a transglutaminase (TGM) polypeptide (e.g., a Transglutaminase-1 (TGM1) polypeptide); viruses comprising the recombinant nucleic acids; compositions comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.
Suma Krishnan, Pooja Agarwal, John C. Freedman, Mark E. O'Malley, Lauren K. Regula
Filed: 10 Apr 19
Utility
Recombinant Nucleic Acids Encoding Cosmetic Protein(s) for Aesthetic Applications
30 Oct 19
The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding one or more cosmetic proteins (e.g., one or more human collagen proteins); viruses comprising the recombinant nucleic acids; compositions (e.g., cosmetic formulations) comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.
Suma KRISHNAN, Trevor PARRY, Pooja AGARWAL
Filed: 25 Apr 19
Utility
Compositions and Methods for the Treatment of Autosomal Recessive Congenital Ichthyosis
16 Oct 19
The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a transglutaminase (TGM) polypeptide (e.g., a Transglutaminase-1 (TGM1) polypeptide); viruses comprising the recombinant nucleic acids; compositions comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.
Suma KRISHNAN, Pooja AGARWAL, John C. FREEDMAN, Mark E. O'MALLEY, Lauren K. REGULA
Filed: 10 Apr 19
Utility
Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
14 Oct 19
The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject.
Suma Krishnan, Pooja Agarwal
Filed: 30 Oct 18